AGIO Agios Pharmaceuticals Inc

NASDAQ
$33.22

Agios Pharmaceuticals Inc (AGIO) Insider Activity

What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.

30D 90D 6M 1Y
Insider signal In line Selling ran in line with AGIO's own trailing one-year pace, with 97% of sale value under a prearranged plan.
Cluster activity 0 buyers in the last 30 days 0 buyers in the last 90 days 1 seller in the last 90 days
Insiders buying
0
0 transactions
Insiders selling
8
44 transactions
Purchases
$0
0 shares
Sales
$4.9M
157,852 shares
Net activity
-$4.9M
purchases less sales

How much of that selling was preplanned? 97% planned / 3% discretionary

10b5-1 plan sales $4.8M 43 transactions · 152,580 shares
Discretionary sales $152.3K 1 transaction · 5,272 shares

Largest single sale: $914.4K.

Where they traded

Buy Sell Dot area is proportional to transaction value.

No open-market insider purchase on record.

Recent open-market activity

Date Insider Role Action Shares Price Value Held after
Gheuens Sarah Chief Medical Officer Sell 10b5-1 30,000 $30.48 $914.4K 54,645 −35.4% of holding
Gheuens Sarah Chief Medical Officer Sell 10b5-1 4,007 $37.56 $150.5K 84,645 −4.5% of holding
Goff Brian 2 fills Chief Executive Officer Sell 10b5-1 19,068 $34.71 $661.9K 184,508 −9.4% of holding
Burns James William Chief Legal Officer Sell 10b5-1 3,280 $34.71 $113.8K 49,306 −6.2% of holding
Milanova Tsveta Chief Commercial Officer Sell 10b5-1 3,262 $34.71 $113.2K 46,829 −6.5% of holding
Jones Cecilia Chief Financial Officer Sell 10b5-1 3,141 $34.71 $109.0K 54,998 −5.4% of holding
Viswanadhan Krishnan Chief Corp Dev & Strategy Sell 10b5-1 2,959 $34.71 $102.7K 10,282 −22.3% of holding
Gheuens Sarah Chief Medical Officer Sell 10b5-1 2,940 $34.71 $102.0K 80,277 −3.5% of holding
Viswanadhan Krishnan Chief Corp Dev & Strategy Sell 10b5-1 2,959 $27.80 $82.3K 5,141 −36.5% of holding
Washburn Theodore James Jr. Principal Accounting Officer Sell 5,272 $28.88 $152.3K 868 −85.9% of holding
Goff Brian 3 fills Chief Executive Officer Sell 10b5-1 18,055 $28.96 $522.9K 164,548 −9.9% of holding
Burns James William 4 fills Chief Legal Officer Sell 10b5-1 5,218 $28.96 $151.1K 44,086 −10.6% of holding
Jones Cecilia 4 fills Chief Financial Officer Sell 10b5-1 5,035 $28.96 $145.8K 49,328 −9.3% of holding
Gheuens Sarah 3 fills Chief Medical Officer Sell 10b5-1 4,055 $28.96 $117.4K 74,406 −5.2% of holding
Milanova Tsveta 2 fills Chief Commercial Officer Sell 10b5-1 2,868 $28.96 $83.1K 41,591 −6.5% of holding
Washburn Theodore James Jr. 3 fills Principal Accounting Officer Sell 10b5-1 2,223 $28.96 $64.4K 6,140 −26.6% of holding
Milanova Tsveta Chief Commercial Officer Sell 10b5-1 2,872 $27.02 $77.6K 34,793 −7.6% of holding
Goff Brian 2 fills Chief Executive Officer Sell 10b5-1 18,703 $27.09 $506.7K 143,103 −11.6% of holding
Jones Cecilia Chief Financial Officer Sell 10b5-1 2,932 $27.09 $79.4K 37,394 −7.3% of holding
Gheuens Sarah Chief Medical Officer Sell 10b5-1 2,932 $27.09 $79.4K 64,795 −4.3% of holding
Burns James William Chief Legal Officer Sell 10b5-1 2,932 $27.09 $79.4K 31,718 −8.5% of holding
Milanova Tsveta Chief Commercial Officer Sell 10b5-1 2,932 $27.09 $79.4K 29,190 −9.1% of holding
Scadden David Director Sell 10b5-1 200 $43.84 $8.8K 17,603 −1.1% of holding
Gheuens Sarah Chief Medical Officer Sell 10b5-1 2,454 $43.78 $107.4K 61,727 −3.8% of holding
Gheuens Sarah Chief Medical Officer Sell 10b5-1 200 $43.81 $8.8K 61,727 −0.3% of holding
Gheuens Sarah Chief Medical Officer Sell 10b5-1 3,302 $43.92 $145.0K 61,727 −5.1% of holding
Scadden David Director Sell 10b5-1 200 $41.00 $8.2K 17,603 −1.1% of holding
Scadden David Director Sell 10b5-1 200 $40.00 $8.0K 17,603 −1.1% of holding
Jones Cecilia Chief Financial Officer Sell 10b5-1 3,651 $36.77 $134.2K 33,870 −9.7% of holding

Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.